Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage

Journal of Neurochemistry

Volumn 88, Issue 3, 2004, Pages 538-544

  Fink, J Stephen ^a   Kalda, Anti ^a   Ryu, Hoon ^a   Stack, Edward C ^a   Schwarzschild, Michael A ^c   Chen, Jiang Fan ^a,b   Ferrante, Robert J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

3 nitropropionic acid; 8 C3 chlorostyryl caffeine; A2A receptor antagonist; Adenosine A2A receptor; Huntington disease; Mitochondrial toxin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; 8 (3 CHLOROSTYRYL)CAFFEINE; ADENOSINE A2A RECEPTOR; DOPAMINE; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONGENIC STRAIN; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MOUSE; MOUSE STRAIN; NEOSTRIATUM; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; STRIATE CORTEX;

ANIMALS; CAFFEINE; CORPUS STRIATUM; FEMALE; GENE SILENCING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRO COMPOUNDS; PROPIONIC ACIDS; RECEPTOR, ADENOSINE A2A;

ANIMALIA;

EID: 0942298557     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02145.x     Document Type: Article

References (51)

1. Alfinto P. D., Manzino L. and Sonsalla P. K. (2002) Adenosine A2a receptor blockade protects striatal dopaminergic and GABAergic neurons in an energy impairment model of neurodegenerative disease. 32nd Annual Meeting of Society for Neuroscience, Orlando, FL.
2. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M, Morris M. J., Mouradian M. M. and Chase T. N. (2003) Adenosine A (2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293-296.
3. Beal M. F. (1994) Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. 7, 542-547.
4. Beal M. F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23, 298-304.
5. Beal M. F. and Hantraye P. (2001) Novel therapies in the search for a cure for Huntington's disease. Proc. Natl Acad. Sci. USA 98, 3-4.
6. Beal M. F., Ferrante R. J., Swartz K. J. and Kowall N. W. (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11, 1649-1659.
7. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R. and Hyman B. T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192.
8. Blum D., Galas M. C., Gall D., Cuvelier L. and Schiffmann S. N. (2002a) Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis 10, 410-426.
9. Blum D., Gall D., Galas M. C., d'Alcantara P., Bantubungi K. and Schiffmann S. N. (2002b) The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22, 9122-9133.
10. Blum D., Galas M. C., Pintor A. et al. (2003) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23, 5361-5369.
11. Brouillet E., Hantraye P., Ferrante R. J., Dolan R., Kowall N. W. and Beal M. F. (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci. USA 92, 7105-7109.
12. Brouillet E., Conde F., Beal M. F. and Hantraye P. (1999) Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
13. Browne S. E., Bowling A. C., MacGarvey U., Baik M. J., Berger S. C., Muqit M. M., Bird E. D. and Beal M. F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653.
14. Carswell H. V., Graham D. I. and Stone T. W. (1997) Kainate-evoked release of adenosine from the hippocampus of the anaesthetised rat: possible involvement of free radicals. J. Neurochem. 68, 240-247.
15. Cha J. H., Frey A. S., Alsdorf S. A., Kerner J. A., Kosinski C. M., Mangiarini L., Penney J. B. Jr, Davies S. W., Bates G. P. and Young A. B. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil. Trans. R. Soc. Lond. B Biol. Sci. 354, 981-989.
16. Chen J. F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., Moskowitz M. A., Fink J. S. and Schwarzschild M. A. (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19, 9192-9200.
17. Chen J. F., Xu K., Petzer J. P., Staal R., Xu Y. H., Beilstein M., Sonsalla P. K., Castagnoli K., Castagnoli N. Jr and Schwarzschild M. A. (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143.
18. Dall'lgna O. P., Porciuncula L. O., Souza D. O., Cunha R. A. and Lara D. R. (2003) Neuroprotection by caffeine and adenosine A(2A) receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 138, 1207-1209.
19. Delaney S. M. and Geiger J. D. (1998) Levels of endogenous adenosine in rat striatum. II. Regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. J. Pharmacol. Exp. Ther. 285, 568-572.
20. Delaney S. M., Shepel P. N. and Geiger J. D. (1998) Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals. J. Pharmacol. Exp. Ther. 285, 561-567.
21. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P. and Aronin N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
22. Dunwiddie T. V. and Masino S. A. (2001) The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24, 31-55.
23. Ferrante R. J., Andreassen O. A., Dedeoglu A., Kuemmerle S., Kubilus J. K., Kaddurah-Daouk R., Hersch S. M. and Beal M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397.
24. Ferrante R. J., Andreassen O. A., Dedeoglu A., Ferrante K. L., Jenkins B. J., Hersch S. M. and Beal M. F. (2002) Therapeutic effects of Coenzyme Q10 and remacemide in transgenic models of Huntington's disease. J. Neurosci. 22, 1592-1599.
25. Fink J. S., Weaver D. R., Rivkees S. A., Peterfreund R. A., Pollack A. E., Adler E. M. and Reppert S. M. (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186-195.
26. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., Impagnatiello F., Schwarzschild M. A. and Chen J. F. (2002) Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 1054-1062.
27. Glass M., Dragunow M. and Faull R. L. (2000) The pattern of neuro-degeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519.
28. Gusella J. F. and MacDonald M. E. (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1, 109-115.
29. Hauser R. A., Hubble J. P. and Truong D. D. (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61, 297-303.
30. Hettinger B. D., Lee A., Linden J. and Rosin D. L. (2001) Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431, 331-346.
31. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
32. Ikeda K., Kurokawa M., Aoyama S. and Kuwana Y. (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80, 262-270.
33. Jones P. A., Smith R. A. and Stone T. W. (1998a) Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res. 800, 328-335.
34. Jones P. A., Smith R. A. and Stone T. W. (1998b) Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience 85, 229-237.
35. Luthi-Carter R., Strand A., Peters N. L. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271.
36. Marcoli M., Raiteri L., Bonfanti A., Monopoli A., Ongini E., Raiteri M. and Maura G. (2003) Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45, 201-210.
37. Monopoli A., Lozza G., Forlani A., Mattavelli A. and Ongini E. (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9, 3955-3959.
38. Nash J. E. and Brotchie J. M. (2000) A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20, 7782-7789.
39. Nishizaki T., Nagai K., Nomura T. et al. (2002) A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia 39, 133-147.
40. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P. and Brouillet E. (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97, 521-530.
41. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J. and Greenamyre J. T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 8, 731-736.
42. Phillis J. W. (1995) The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705, 79-84.
43. Popoli P., Pintor A., Domenici M. R. et al. (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22, 1967-1975.
44. Reggio R., Pezzola A. and Popoli P. (1999) The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831, 315-318.
45. Sawa A., Wiegand G. W., Cooper J., Margolis R. L., Sharp A. H., Lawler J. F. Jr, Greenamyre J. T., Snyder S. H. and Ross C. A. (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5, 1194-1198.
46. Schauwecker P. E. and Steward O. (1997) Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc. Natl Acad. Sci. USA 94, 4103-4108.
47. Schiffmann S. N. and Vanderhaeghen J. J. (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13, 1080-1087.
48. Schiffmann S. N., Jacobs O. and Vanderhaeghen J. J. (1991) Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57, 1062-1067.
49. Sebastiao A. M. and Ribeiro J. A. (2000) Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci. 21, 341-346.
50. Spektor B. S., Miller D. W., Hollingsworth Z. R., Kaneko Y. A., Solano S. M., Johnson J. M., Penney J. B. Jr, Young A. B. and Luthi-Carter R. (2002) Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res. Mol. Brain Res. 102, 118-128.
51. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P. Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.